BRAF and colorectal cancer: We previously demonstrated the therapeutic efficacy of encorafenib (BRAF inhibitor) in combination with the epidermal growth factor receptor (EGFR) inhibitor cetuximab for the treatment of patients with advanced colorectal cancer (21).